Asia Pacific Erythropoietin Drugs Market By Drug Class, By Product, By Application, By Country, Growth Potential, Industry Analysis Report and Forecast, 2021 - 2027

The Asia Pacific Erythropoietin Drugs Market would witness market growth of 13.2% CAGR during the forecast period (2021-2027).

The increasing incidences of chronic diseases like cancer, end-stage renal diseases, and HIV are likely to boost the demand for EPO-stimulating agents. These diseases have the potential to cause anaemia. To control the increasing cases of anaemia, the demand for Erthropotin (EPO) drugs would witness a surge in the forthcoming years.

The molecular weight of erythropoietin is about 30,400 daltons. It is generated by mammalian cells in which the gene of the human erythropoietin gene is introduced. The product acts similar to natural erythropoietin and retains biological activity in the same manner as endogenous erythropoietin. Epoetin alfa biosimilar like Retacrit (epoetin alfa-epbx or epoetin zeta) has a formulation that allows more treatment options for patients suffering from anaemia.

In the Asia Pacific, EPO industry is flourishing due to a continuous increase in the incidence of chronic diseases. There is high demand for low-cost therapeutics in this region. Therefore, the Asia Pacific has attracted many companies for the development of biosimilars. They are focused on developing more biosimilars than any other place on the globe.

Moreover, supportive government initiatives will also provide better health amenities to the public in this region. It is expected to contribute to the EPO drug market growth. For example, the Japanese government's regulation stated that on the price of biosimilars, a discount of 30% should be given and making it available at subsidized prices to people who belong to the lower economic class.

The China market dominated the Asia Pacific Hematology Market by Country in 2020, thereby, achieving a market value of $191 million by 2027. The Japan market is showcasing a CAGR of 15.5% during (2021 - 2027). Additionally, The India market is poised to grow at a CAGR of 15.5% during (2021 - 2027).

Based on Drug Class, the market is segmented into Biologics and Biosimilars. Based on Product, the market is segmented into Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and others. Based on Application, the market is segmented into Renal Diseases, Cancer, Hematology and Neurology. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson and Johnson, Teva Pharmaceuticals Industries Ltd., Amgen, Inc., F. Hoffmann-La Roche Ltd., Biocon Limited, Intas Pharmaceutical Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., LG Corporation (LG Life Sciences Ltd.), and Celltrion, Inc.

Scope of the Study

Market Segments covered in the Report:

By Drug Class

• Biologics
• Biosimilars

By Product

• Epoetin-alfa
• Epoetin-beta
• Darbepoetin-alfa
• others

By Application

• Renal Diseases
• Cancer
• Hematology
• Neurology

By Country

• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific

Companies Profiled

• Johnson and Johnson
• Teva Pharmaceuticals Industries Ltd.
• Amgen, Inc.
• F. Hoffmann-La Roche Ltd.
• Biocon Limited
• Intas Pharmaceutical Ltd.
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories Ltd.
• LG Corporation (LG Life Sciences Ltd.)
• Celltrion, Inc.

Unique Offerings from KBV Research

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

• 1.1 Market Definition
• 1.2 Objectives
• 1.3 Market Scope
• 1.4 Segmentation
  • 1.4.1 Asia Pacific Erythropoietin Drugs Market, by Drug Class
  • 1.4.2 Asia Pacific Erythropoietin Drugs Market, by Product
  • 1.4.3 Asia Pacific Erythropoietin Drugs Market, by Application
  • 1.4.4 Asia Pacific Erythropoietin Drugs Market, by Country
• 1.5 Methodology for the research

Chapter 2. Market Overview

• 2.1 Introduction
  • 2.1.1 Overview
  • 2.1.2 Market composition and scenario
• 2.2 Key Factors Impacting the Market
  • 2.2.1 Market Drivers
  • 2.2.2 Market Restraints

Chapter 3. Asia Pacific Erythropoietin Drugs Market by Drug Class

• 3.1 Asia Pacific Biologics Market by Country
• 3.2 Asia Pacific Biosimilars Market by Country

Chapter 4. Asia Pacific Erythropoietin Drugs Market by Product

• 4.1 Asia Pacific Epoetin-alfa Market by Country
• 4.2 Asia Pacific Epoetin-beta Market by Country
• 4.3 Asia Pacific Darbepoetin-alfa Market by Country
• 4.4 Asia Pacific Other Product Market by Country

Chapter 5. Asia Pacific Erythropoietin Drugs Market by Application

• 5.1 Asia Pacific Renal Diseases Market by Country
• 5.2 Asia Pacific Cancer Market by Country
• 5.3 Asia Pacific Hematology Market by Country
• 5.4 Asia Pacific Neurology Market by Country

Chapter 6. Asia Pacific Erythropoietin Drugs Market by Country

• 6.1 China Erythropoietin Drugs Market
  • 6.1.1 China Erythropoietin Drugs Market by Drug Class
  • 6.1.2 China Erythropoietin Drugs Market by Product
  • 6.1.3 China Erythropoietin Drugs Market by Application
• 6.2 Japan Erythropoietin Drugs Market
  • 6.2.1 Japan Erythropoietin Drugs Market by Drug Class
  • 6.2.2 Japan Erythropoietin Drugs Market by Product
  • 6.2.3 Japan Erythropoietin Drugs Market by Application
• 6.3 India Erythropoietin Drugs Market
  • 6.3.1 India Erythropoietin Drugs Market by Drug Class
  • 6.3.2 India Erythropoietin Drugs Market by Product
  • 6.3.3 India Erythropoietin Drugs Market by Application
• 6.4 South Korea Erythropoietin Drugs Market
  • 6.4.1 South Korea Erythropoietin Drugs Market by Drug Class
  • 6.4.2 South Korea Erythropoietin Drugs Market by Product
  • 6.4.3 South Korea Erythropoietin Drugs Market by Application
• 6.5 Singapore Erythropoietin Drugs Market
  • 6.5.1 Singapore Erythropoietin Drugs Market by Drug Class
  • 6.5.2 Singapore Erythropoietin Drugs Market by Product
  • 6.5.3 Singapore Erythropoietin Drugs Market by Application
• 6.6 Malaysia Erythropoietin Drugs Market
  • 6.6.1 Malaysia Erythropoietin Drugs Market by Drug Class
  • 6.6.2 Malaysia Erythropoietin Drugs Market by Product
  • 6.6.3 Malaysia Erythropoietin Drugs Market by Application
• 6.7 Rest of Asia Pacific Erythropoietin Drugs Market
  • 6.7.1 Rest of Asia Pacific Erythropoietin Drugs Market by Drug Class
  • 6.7.2 Rest of Asia Pacific Erythropoietin Drugs Market by Product
  • 6.7.3 Rest of Asia Pacific Erythropoietin Drugs Market by Application

Chapter 7. Company Profiles

• 7.1 Johnson and Johnson
  • 7.1.1 Company Overview
  • 7.1.2 Financial Analysis
  • 7.1.3 Segmental &Regional Analysis
  • 7.1.4 Research & Development Expenses
  • 7.1.5 Recent strategies and developments:
    • 7.1.5.1 Approvals:
• 7.2 Teva Pharmaceutical Industries Ltd.
  • 7.2.1 Company Overview
  • 7.2.2 Financial Analysis
  • 7.2.3 Regional Analysis
  • 7.2.4 Research & Development Expenses
• 7.3 Amgen, Inc.
  • 7.3.1 Company Overview
  • 7.3.2 Financial Analysis
  • 7.3.3 Regional Analysis
  • 7.3.4 Research & Development Expenses
  • 7.3.5 Recent strategies and developments:
    • 7.3.5.1 Partnerships, Collaborations, and Agreements:
• 7.4 F. Hoffmann-La Roche Ltd.
  • 7.4.1 Company Overview
  • 7.4.1 Financial Analysis
  • 7.4.2 Segmental and Regional Analysis
  • 7.4.3 Research & Development Expense
• 7.5 Biocon Limited
  • 7.5.1 Company Overview
• 7.6 Intas Pharmaceutical Ltd.
  • 7.6.1 Company Overview
• 7.7 Sun Pharmaceutical Industries Ltd.
  • 7.7.1 Company Overview
  • 7.7.2 Financial Analysis
  • 7.7.3 Regional Analysis
  • 7.7.4 Research & Development Expense
• 7.8 Dr. Reddy's Laboratories Ltd.
  • 7.8.1 Company Overview
  • 7.8.2 Financial Analysis
  • 7.8.3 Segmental and Regional Analysis
  • 7.8.4 Research & Development Expense
• 7.9 LG Corporation (LG Life Sciences Ltd.)
  • 7.9.1 Company Overview
  • 7.9.2 Financial Analysis
  • 7.9.3 Segmental and Regional Analysis
• 7.10. Celltrion, Inc.
  • 7.10.1 Company Overview

LIST OF TABLES

• TABLE 1 Asia Pacific Erythropoietin Drugs Market, 2017 - 2020, USD Million
• TABLE 2 Asia Pacific Erythropoietin Drugs Market, 2021 - 2027, USD Million
• TABLE 3 Asia Pacific Erythropoietin Drugs Market by Drug Class, 2017 - 2020, USD Million
• TABLE 4 Asia Pacific Erythropoietin Drugs Market by Drug Class, 2021 - 2027, USD Million
• TABLE 5 Asia Pacific Biologics Market by Country, 2017 - 2020, USD Million
• TABLE 6 Asia Pacific Biologics Market by Country, 2021 - 2027, USD Million
• TABLE 7 Asia Pacific Biosimilars Market by Country, 2017 - 2020, USD Million
• TABLE 8 Asia Pacific Biosimilars Market by Country, 2021 - 2027, USD Million
• TABLE 9 Asia Pacific Erythropoietin Drugs Market by Product, 2017 - 2020, USD Million
• TABLE 10 Asia Pacific Erythropoietin Drugs Market by Product, 2021 - 2027, USD Million
• TABLE 11 Asia Pacific Epoetin-alfa Market by Country, 2017 - 2020, USD Million
• TABLE 12 Asia Pacific Epoetin-alfa Market by Country, 2021 - 2027, USD Million
• TABLE 13 Asia Pacific Epoetin-beta Market by Country, 2017 - 2020, USD Million
• TABLE 14 Asia Pacific Epoetin-beta Market by Country, 2021 - 2027, USD Million
• TABLE 15 Asia Pacific Darbepoetin-alfa Market by Country, 2017 - 2020, USD Million
• TABLE 16 Asia Pacific Darbepoetin-alfa Market by Country, 2021 - 2027, USD Million
• TABLE 17 Asia Pacific Other Product Market by Country, 2017 - 2020, USD Million
• TABLE 18 Asia Pacific Other Product Market by Country, 2021 - 2027, USD Million
• TABLE 19 Asia Pacific Erythropoietin Drugs Market by Application, 2017 - 2020, USD Million
• TABLE 20 Asia Pacific Erythropoietin Drugs Market by Application, 2021 - 2027, USD Million
• TABLE 21 Asia Pacific Renal Diseases Market by Country, 2017 - 2020, USD Million
• TABLE 22 Asia Pacific Renal Diseases Market by Country, 2021 - 2027, USD Million
• TABLE 23 Asia Pacific Cancer Market by Country, 2017 - 2020, USD Million
• TABLE 24 Asia Pacific Cancer Market by Country, 2021 - 2027, USD Million
• TABLE 25 Asia Pacific Hematology Market by Country, 2017 - 2020, USD Million
• TABLE 26 Asia Pacific Hematology Market by Country, 2021 - 2027, USD Million
• TABLE 27 Asia Pacific Neurology Market by Country, 2017 - 2020, USD Million
• TABLE 28 Asia Pacific Neurology Market by Country, 2021 - 2027, USD Million
• TABLE 29 Asia Pacific Erythropoietin Drugs Market by Country, 2017 - 2020, USD Million
• TABLE 30 Asia Pacific Erythropoietin Drugs Market by Country, 2021 - 2027, USD Million
• TABLE 31 China Erythropoietin Drugs Market, 2017 - 2020, USD Million
• TABLE 32 China Erythropoietin Drugs Market, 2021 - 2027, USD Million
• TABLE 33 China Erythropoietin Drugs Market by Drug Class, 2017 - 2020, USD Million
• TABLE 34 China Erythropoietin Drugs Market by Drug Class, 2021 - 2027, USD Million
• TABLE 35 China Erythropoietin Drugs Market by Product, 2017 - 2020, USD Million
• TABLE 36 China Erythropoietin Drugs Market by Product, 2021 - 2027, USD Million
• TABLE 37 China Erythropoietin Drugs Market by Application, 2017 - 2020, USD Million
• TABLE 38 China Erythropoietin Drugs Market by Application, 2021 - 2027, USD Million
• TABLE 39 Japan Erythropoietin Drugs Market, 2017 - 2020, USD Million
• TABLE 40 Japan Erythropoietin Drugs Market, 2021 - 2027, USD Million
• TABLE 41 Japan Erythropoietin Drugs Market by Drug Class, 2017 - 2020, USD Million
• TABLE 42 Japan Erythropoietin Drugs Market by Drug Class, 2021 - 2027, USD Million
• TABLE 43 Japan Erythropoietin Drugs Market by Product, 2017 - 2020, USD Million
• TABLE 44 Japan Erythropoietin Drugs Market by Product, 2021 - 2027, USD Million
• TABLE 45 Japan Erythropoietin Drugs Market by Application, 2017 - 2020, USD Million
• TABLE 46 Japan Erythropoietin Drugs Market by Application, 2021 - 2027, USD Million
• TABLE 47 India Erythropoietin Drugs Market, 2017 - 2020, USD Million
• TABLE 48 India Erythropoietin Drugs Market, 2021 - 2027, USD Million
• TABLE 49 India Erythropoietin Drugs Market by Drug Class, 2017 - 2020, USD Million
• TABLE 50 India Erythropoietin Drugs Market by Drug Class, 2021 - 2027, USD Million
• TABLE 51 India Erythropoietin Drugs Market by Product, 2017 - 2020, USD Million
• TABLE 52 India Erythropoietin Drugs Market by Product, 2021 - 2027, USD Million
• TABLE 53 India Erythropoietin Drugs Market by Application, 2017 - 2020, USD Million
• TABLE 54 India Erythropoietin Drugs Market by Application, 2021 - 2027, USD Million
• TABLE 55 South Korea Erythropoietin Drugs Market, 2017 - 2020, USD Million
• TABLE 56 South Korea Erythropoietin Drugs Market, 2021 - 2027, USD Million
• TABLE 57 South Korea Erythropoietin Drugs Market by Drug Class, 2017 - 2020, USD Million
• TABLE 58 South Korea Erythropoietin Drugs Market by Drug Class, 2021 - 2027, USD Million
• TABLE 59 South Korea Erythropoietin Drugs Market by Product, 2017 - 2020, USD Million
• TABLE 60 South Korea Erythropoietin Drugs Market by Product, 2021 - 2027, USD Million
• TABLE 61 South Korea Erythropoietin Drugs Market by Application, 2017 - 2020, USD Million
• TABLE 62 South Korea Erythropoietin Drugs Market by Application, 2021 - 2027, USD Million
• TABLE 63 Singapore Erythropoietin Drugs Market, 2017 - 2020, USD Million
• TABLE 64 Singapore Erythropoietin Drugs Market, 2021 - 2027, USD Million
• TABLE 65 Singapore Erythropoietin Drugs Market by Drug Class, 2017 - 2020, USD Million
• TABLE 66 Singapore Erythropoietin Drugs Market by Drug Class, 2021 - 2027, USD Million
• TABLE 67 Singapore Erythropoietin Drugs Market by Product, 2017 - 2020, USD Million
• TABLE 68 Singapore Erythropoietin Drugs Market by Product, 2021 - 2027, USD Million
• TABLE 69 Singapore Erythropoietin Drugs Market by Application, 2017 - 2020, USD Million
• TABLE 70 Singapore Erythropoietin Drugs Market by Application, 2021 - 2027, USD Million
• TABLE 71 Malaysia Erythropoietin Drugs Market, 2017 - 2020, USD Million
• TABLE 72 Malaysia Erythropoietin Drugs Market, 2021 - 2027, USD Million
• TABLE 73 Malaysia Erythropoietin Drugs Market by Drug Class, 2017 - 2020, USD Million
• TABLE 74 Malaysia Erythropoietin Drugs Market by Drug Class, 2021 - 2027, USD Million
• TABLE 75 Malaysia Erythropoietin Drugs Market by Product, 2017 - 2020, USD Million
• TABLE 76 Malaysia Erythropoietin Drugs Market by Product, 2021 - 2027, USD Million
• TABLE 77 Malaysia Erythropoietin Drugs Market by Application, 2017 - 2020, USD Million
• TABLE 78 Malaysia Erythropoietin Drugs Market by Application, 2021 - 2027, USD Million
• TABLE 79 Rest of Asia Pacific Erythropoietin Drugs Market, 2017 - 2020, USD Million
• TABLE 80 Rest of Asia Pacific Erythropoietin Drugs Market, 2021 - 2027, USD Million
• TABLE 81 Rest of Asia Pacific Erythropoietin Drugs Market by Drug Class, 2017 - 2020, USD Million
• TABLE 82 Rest of Asia Pacific Erythropoietin Drugs Market by Drug Class, 2021 - 2027, USD Million
• TABLE 83 Rest of Asia Pacific Erythropoietin Drugs Market by Product, 2017 - 2020, USD Million
• TABLE 84 Rest of Asia Pacific Erythropoietin Drugs Market by Product, 2021 - 2027, USD Million
• TABLE 85 Rest of Asia Pacific Erythropoietin Drugs Market by Application, 2017 - 2020, USD Million
• TABLE 86 Rest of Asia Pacific Erythropoietin Drugs Market by Application, 2021 - 2027, USD Million
• TABLE 87 Key information -Johnson and Johnson
• TABLE 88 Key Information - Teva Pharmaceuticals Industries Ltd.
• TABLE 89 Key Information - Amgen, Inc.
• TABLE 90 key information - F. Hoffmann-La Roche Ltd.
• TABLE 91 Key Information - Biocon Limited
• TABLE 92 Key Information - Intas Pharmaceutical Ltd.
• TABLE 93 Key Information - Sun Pharmaceutical Industries Ltd.
• TABLE 94 key information - Dr. Reddy's Laboratories Ltd.
• TABLE 95 Key Information - LG Corporation
• TABLE 96 key information - Celltrion, Inc.

List of Figures

• FIG 1 Methodology for the research